Medicus Pharma(MDCX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Medicus Pharma
MDCX.US
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd.
1.850 T
MDCX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Medicus Pharma shares are trading higher after the company announced results from pre-specified expanded Phase 2 SKNJCT-003 data analysis.

    benzinga_article·
    US
    MDCX
    -1.38%
    benzinga_article·
    US
    MDCX
    -1.38%

    EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study

    benzinga_article·
    US
    MDCX
    -1.38%
    benzinga_article·
    US
    MDCX
    -1.38%

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    benzinga_article·
    US
    OGN
    -0.30%
    US
    MDCX
    -1.38%
    US
    SGMT
    +5.26%
    benzinga_article·
    US
    OGN
    -0.30%
    US
    MDCX
    -1.38%
    US
    SGMT
    +5.26%

    Medicus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard

    TradingView·
    US
    MDCX
    -1.38%
    TradingView·
    US
    MDCX
    -1.38%

    Medicus Pharma Upsizes ATM Program to $50 Million With Maxim Group and Yorkville Securities

    TradingView·
    US
    MDCX
    -1.38%
    TradingView·
    US
    MDCX
    -1.38%
    © 2026 Longbridge｜Disclaimer